High Risk Anatomy Challenges ISCHEMIA Outcomes

According to this recent analysis published in JAHA, patients with stable Ischemic heart disease and high-risk anatomy benefit from revascularization at long term vs. the conservative treatment. 

Ischemia

This goes against the study presented by Reynolds H et al at AHA 2020. Dr. Reynold’s was a sub-study of the ISCHEMIA trial which had observed that even though anatomical complexity impacts prognosis, it cannot be modified by revascularization. 

The ISCHEMIA, published in NEJM, and all its sub studies, came to question everything we used to believe about chronic ischemic cardiomyopathy.  However, more and more studies shed light on the recommended strategies. 

9016 patients with stable ischemic heart disease and high-risk anatomy where included (3 vessels with >70% lesion, left main with >50% lesion or a combination of both).

The primary end point of all cause death or acute myocardial infarction was compared between patients receiving revascularization and those treated conservatively.


Read also: Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence.


5487 (61%) of patients received CABG (n=3312) or PCI (n=2175), whereas the remaining 3529 (39%) were managed conservatively.

Revascularization was associated with reduced MI rate and all cause rate. In addition, it was associated with longer life expectancy compared against the conservative treatment (p<0.001 for all points). 

Reduced events rate was similar between CABG (HR 0.64, CI 95% 0.59 to 0.70, p<0.001) and PCI (HR 0.61; CI 95% 0.57 to 0.66; p<0.001).

Conclusion

Revascularization in patient with stable ischemic heart disease and high-risk anatomy improves prognosis at long term compared against the conservative treatment. Coronary anatomy should be considered before recommending revascularization to treat these patients. 

JAHA-120-018104

Original Title: Long-Term Clinical Outcomes Following Revascularization in High-Risk Coronary Anatomy Patients With Stable Ischemic Heart Disease.

Reference: Kevin R. Bainey et al. J Am Heart Assoc. 2021;10:e018104.  DOI: 10.1161/JAHA.120.018104.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...